New FDA Vaccine Chief Sparks Pharma Stock Volatility and Policy Concerns

New Leadership at FDA Vaccines Division

• 🎯 Vanai Prasad, a vocal critic of the FDA, has been appointed as the new director of vaccines.
• 💡 Prasad has previously criticized annual COVID boosters as a failure of FDA regulation and questioned the use of accelerated approvals.
• ⚠️ He has also accused his predecessor, Peter Marx, of "rubber stamping" drugs, advocating for cancer drugs to demonstrate longer survival rates rather than just tumor shrinkage.

Broader Industry Pressures

• 📉 Pharmaceutical stocks experienced a significant downturn following Prasad's appointment.
• 📌 The industry is facing multiple pressures, including uncertainty following RFK Jr.'s appointment as HHS secretary and the proposed most favored nations drug policy.
• 💰 The most favored nations policy, if added to the reconciliation bill, would tie drug prices in Medicaid to the lowest prices paid by other countries, potentially impacting the 340B program.

Industry Response and Other Concerns

• 🚨 Pharma CEOs held an emergency call and are actively lobbying on Capitol Hill due to these policy concerns.
• 📈 In addition to policy shifts, the industry is also awaiting decisions on tariffs related to a Section 232 investigation, with an announcement expected within two weeks.
• ⚖️ Some industry executives view the most favored nations policy as a potentially larger threat than pharmaceutical tariffs.